tetherex.comHealthcareFounded: 2002Funding to Date: $68.65MM
Developer of drugs for the treatment of inflammatory and thrombotic diseases. The company's treatment program is built around an antibody called SelK2 directed against the cell adhesion molecule P-Selectin Glycoprotein Ligand-1 (PSGL-1).
View Enterprise Value for Tetherex Pharmaceuticals.